The race to launch first weight-loss pill
The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables.
Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs.
Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market:
Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up.
Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial.
The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations.
Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter.
The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies.
AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead.
Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year.
The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism.
In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo.
Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
7 minutes ago
- Daily Mail
Morrisons fights to stay in top five: Struggling grocer now taking in just £4m a week more than Lidl
Morrisons is now taking in just £4million a week more than Lidl – setting the scene for it to be overtaken by its discount rival. The beleaguered supermarket has already been elbowed out of the top four by Aldi and is close to being eclipsed by its other German budget rival. Industry figures yesterday revealed that Lidl is almost neck and neck with Morrisons after sales rose 10.7 per cent to just under £3billion in the 12 weeks to August 10. Sales at Morrisons were just £48million higher over the period having risen by only 0.9 per cent, according to the report by research group Worldpanel. And while Lidl's share of the market has jumped from 7.8 per cent to 8.3 per cent in the past year, Morrisons has seen its slice fall from 8.7 per cent to 8.4 per cent. Analysts said they are confident Lidl will overtake Morrisons in the coming weeks as it presses ahead with a rollout of new stores. Clive Black, retail analyst at Shore Capital, said: 'Lidl and Morrisons are neck and neck when it comes to UK market share. The German discounter will take the lead in the near future because it is opening new stores while Morrisons is not and it has stronger underlying trading momentum.' Lidl plans to open a total of 40 sites by the end of the year, and it seeks to reach 1,000 stores over the next few years. It also has a 'very strong private label that it has curated through single ownership with a long-term view for many years', Black added. Morrisons has lost sales and market share to rivals since its takeover by Clayton, Dubilier & Rice in a debt-fuelled £7billion deal in October 2021. Black said the takeover 'stopped decent pre-existing trading momentum and materially burdened the supermarket with debt servicing costs that have, in reality, starved the business of the resources necessary to allow it to compete more effectively'. After Labour piled on costs for retailers at the Budget last year, Morrisons cut more than 350 jobs in March.
The Sun
7 minutes ago
- The Sun
Lidl to set overtake Morrisons as Britain's fifth biggest supermarket as shoppers turn to cheaper food
LIDL is due to overtake Morrisons as Britain's fifth biggest supermarket — as shoppers turn to cheaper food to offset higher costs. The latest data shows that the discount option makes up 8.3 per cent of the grocery market against Morrisons' 8.4 per cent, analysts Worldpanel revealed yesterday. And Lidl increased its sales by 10.7 per cent in the three months to August — more than ten times that at Morrisons, whose sales rose by just 0.9 per cent in the same period. The German retailer is now the fastest-growing supermarket in the UK, alongside Ocado. Meanwhile, at Asda, sales were down 2.6 per cent on a year ago, and the Co-Op's fell by 3.2 per cent. Recent data also brought good news for shoppers as supermarket inflation fell slightly in August, down to five per cent. But Fraser McKevitt, Worldpanel's head of retail and consumer insight, warned: 'We're still well past the point at which price rises really start to bite and consumers are continuing to adapt their behaviour to make ends meet.' He said cost pressures were continuing to hit the High Street, noting a decline in eating out in casual restaurants lately. But shoppers still appear to want their treats, with branded groceries seeing more sales growth this month than cheaper own-label options. COVID BOOSTER THE economy recovered from the pandemic better than thought, the Office for National Statistics (ONS) has said. Revised data, based on how gross domestic product is calculated, showed the economy was 2.2 per cent larger at the end of 2023 than its peak shortly before Covid. It had been reported at 1.9 per cent. The ONS added: 'The long-term pattern of growth is broadly unchanged.' THE final coins featuring Queen Elizabeth II's portrait are to enter circulation from today, The Royal Mint has announced. More than 30million new £1 coins will be released this week, including more than 23million featuring the late Queen. The release also includes 170,000 £1 coins bearing the official portrait of King Charles III. Royal Mint director Rebecca Morgan said: 'This represents a pivotal moment.' THE HEAT'S TURNING UP MILLIONS will see their energy bills rise to £1,737 in October when the price cap rises by one per cent, industry analysts predict. An annual rise of £17 has been predicted by Cornwall Insight ahead of Ofgem's official confirmation next Wednesday. The latest forecast reverses the consultants' previous forecast in July that bills would instead drop by one per cent due to easing tensions in the Middle East. It said its forecast reflected changes to schemes like the expansion of the Warm Home Discount which gives struggling homes a £150 grant towards their bill.
Reuters
37 minutes ago
- Reuters
TRADING DAY Tech it down a notch
ORLANDO, Florida, Aug 19 (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist Wall Street slumped on Tuesday, dragged down by weakness in some of the big tech companies that have led the charge to new highs this year, as investors hunker down ahead of a keynote speech by Fed Chair Jerome Powell later this week. More on that below. In my column today I look at the cagey dance between Donald Trump and Wall Street - the market knows it has the power to rein in some of the president's policy excesses, but isn't wielding it. Not yet, anyway. If you have more time to read, here are a few articles I recommend to help you make sense of what happened in markets today. Today's Key Market Moves Today's Talking Points: * Peace in our time? Investors digested the extraordinary summit between U.S. President Donald Trump, Ukraine President Volodymyr Zelenskiy, and a phalanx of European leaders in the White House on Monday. Did it move the dial much on the prospects of a Russia-Ukraine ceasefire, or a deal to end the war? Optimism around Trump's promise of security guarantees for Ukraine in the future buoyed European markets on Tuesday. But that evaporated as the U.S. session rolled on, as Trump told Fox News he thinks Russian President Vladimir Putin may not want to make a deal after all. There may be no immediate direct impact on major equity, bond, or currency markets from the conflict. But prolonged war on Europe's doorstep, fractured ties between the US and Europe, and a fickle relationship between Trump and Putin can't be good in the long term. * Retail therapy. Some of America's biggest retailers report second-quarter earnings this week, shining a light on the health of the U.S. consumer and, by extension, the economy at large. Home Depot reported on Tuesday; Lowe's, Target, and TJX release results on Wednesday; and Walmart is out on Thursday. There are conflicting signals coming from the U.S. consumer. By some measures, household consumption flat-lined in the first half of the year, but other indicators show consumer spending is the biggest contributor to GDP growth. The rich are spending, but the bottom 50% are struggling. The S&P 500's consumer discretionary sector is flat this year, and the consumer staples index is up 6%. Both are lagging the broader index, which is up 8%, and the IT and communications sectors, which are both up around 13%. * Interest rate decisions. The central banks of New Zealand, Indonesia, and China announce their latest policy decisions on Wednesday. Two of the three are expected to stand pat, and one is expected to cut borrowing costs. The People's Bank of China is expected to keep benchmark one- and five-year lending rates unchanged for the third straight month at 3.5% and 5.5%, respectively. Although the economy needs more support, the central bank may want to explore structural policies aimed at specific sectors rather than broad-based monetary easing. For now. This has helped propel a recovery in the yuan, which was plumbing 17-year lows at the depths of the "Liberation Day" tariff turmoil in April. Since then, the PBOC has only lowered borrowing costs once, by 10 basis points, and has fixed the yuan higher in 16 of the last 19 weeks. Markets, Trump in delicate policy dance U.S. President Donald Trump has faced little opposition in his drive to rip up the global economic rulebook, whether from his fellow Republicans, political opponents, or institutional guardrails. The only exception has been "the market." But now even investors are holding their fire, enabling more risk to build up in the financial system. Wall Street's reaction to Trump's "Liberation Day" tariffs on April 2 was so ferocious that the president did something he had rarely done: he backed down. Trillions of dollars were wiped off the value of U.S. stocks amid a 10% nosedive from April 3-4. The only two-day selloffs since the 1930s that were bigger occurred during the Second World War, "Black Monday" in 1987, the Global Financial Crisis in 2008, and the pandemic in 2020. The stock market bottomed out on April 7 after Trump paused most of his country-specific tariffs. Wall Street has not looked back since, with the S&P 500 rebounding 35% to an all-time high. This episode suggests that "the market" is one of the few true checks on Trump's apparent pursuit to reshape the U.S. – and indeed the world – economy. The only problem is that the president has continued to pursue unorthodox policies in recent months - including challenging the independence of the Federal Reserve, firing statisticians, and slapping tariffs on countries for non-economic reasons – and investors have failed to tap the brakes. The so-called "Trump put" -- the idea that the president won't let the markets fall too far -- is essentially a funhouse mirror version of the famous "Fed put," the long-held belief that, in the event of a crisis, the central bank will step in to restore stability. Trump seemingly did just that in April, but it was to clean up a mess of his own making. And one could argue that it was actually investors who came to the economy's rescue by putting pressure on the president to reconsider policies considered ill-advised by most economists. Trump and markets are therefore now in a curious dance. Investors appear to believe that markets can ultimately stop Trump from pushing the envelope too far on tariffs or other policies. But as a result, investors are not overreacting – or reacting at all – to the latest controversies around the Bureau of Labor Statistics firing, his attacks on Fed Chair Jerome Powell, his pressure on Intel's CEO to resign, or the outsized tariffs slapped on Brazil and India. This, in turn, has powered the markets to new record highs, emboldening Trump to push the envelope even further. So even though the market has the power to rein in the president's economic policy excesses, it's not using it. Why hasn't the market pushed back? As the cliche goes, equity investors are paid to be optimistic. It's in their interest to keep the train hurtling along, provided there aren't any immediate obstacles to derail it. There are, of course, a few pretty large hurdles on the horizon for the U.S. economy, including the highest tariffs since the 1930s and some of the biggest budget deficits since World War II outside of crisis periods. But until these or other issues present an immediate economic threat, markets can choose to ignore them. By under-reacting to Trump's unorthodox policies, markets may not only delay the day of reckoning but also amplify the potential impact. Why? Genuine economic and geopolitical paradigm shifts are under way, and investors are not pricing in the attendant risk. Nobody knows what the ultimate impact of these shifts will be, but we do know that with greater uncertainty comes greater downside risk. Yet equity volatility is the lowest it has been this year, and even in the bond market – not known for its optimism – volatility is the lowest in three and a half years, while U.S. corporate bond spreads are the tightest since 1998. Ultimately, the market is unlikely to call Trump's bluff until something truly unexpected or extreme hits. In the meantime, investors can justify this nonchalance by saying that corporate earnings growth is solid, AI enthusiasm is high, economic growth remains decent, unemployment is low, and consumers are still spending. Wall Street is choosing not to put on the brakes, meaning this train will continue rolling on. Whether it's heading for a collision is an open question. What could move markets tomorrow? Want to receive Trading Day in your inbox every weekday morning? Sign up for my newsletter here. Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, opens new tab, is committed to integrity, independence, and freedom from bias.
